Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study

Commissioned by Bayer plc.

Information intended for UK healthcare professionals only.

This promotional eLearning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines. Please see the bottom of the page for full disclaimer.

View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   

 

Module objectives

After completing this activity, you should be able to:

  • discuss the importance of stroke prevention in patients with atrial fibrillation
  • understand how to assess stroke and bleeding risk in your patients
  • discuss the NICE guidance supporting the use of direct oral anticoagulants (DOACs) in patients with atrial fibrillation
  • counsel patients considering transitioning from warfarin to a DOAC.

Now that you have viewed the module, answer MCQs to test your knowledge and receive an email with your CPD certificate:

 

This eLearning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines. Bayer plc suggested the topic and presenters, and carried out full medical approval on all materials to ensure compliance with the ABPI code of practice. Bayer plc contracted and paid the presenters honoraria. The views and opinions expressed in the module are not necessarily those of Guidelines, its publisher, advisers, or advertisers. No part of this module may be reproduced in any form without the permission of the publisher.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc. Tel.: 0118 206 3500, Fax.: 0118 206 3703, Email: pvuk@bayer.com

PP-XAR-GB-2411

Date of preparation: January 2022